2018 |
Al-Hiyali, M I; Ishak, A J; Harun, H; Ahmad, S A; Sulaiman, Wan W A A review in modification food-intake behavior by brain stimulation: Excess weight cases Journal Article NeuroQuantology, 16 (12), pp. 86-97, 2018, ISSN: 13035150, (cited By 2). Abstract | Links | BibTeX | Tags: Amygdala, Anoxia, Article, Autism, Binge Eating Disorder, Body Mass, Body Weight, Brain Depth Stimulation, Depolarization, Dietary Intake, Drug Craving, Eating Disorder, Electric Current, Electroencephalogram, Electroencephalography, Energy Consumption, Energy Expenditure, Feeding Behavior, Food Intake, Functional Magnetic Resonance Imaging, Gender, Health Status, Homeostasis, Human, Hunger, Lifestyle, Nerve Cell Membrane Steady Potential, Nerve Excitability, Neurofeedback, Neuromodulation, Nutritional Assessment, Outcome Assessment, Questionnaires, Repetitive Transcranial Magnetic Stimulation, Signal Processing, Training, Transcranial Direct Current Stimulation, Transcranial Magnetic Stimulation, Underweight @article{Al-Hiyali201886, title = {A review in modification food-intake behavior by brain stimulation: Excess weight cases}, author = {M I Al-Hiyali and A J Ishak and H Harun and S A Ahmad and W A Wan Sulaiman}, url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062843670&doi=10.14704%2fnq.2018.16.12.1894&partnerID=40&md5=235f66cef05a144be23472641f70bd1d}, doi = {10.14704/nq.2018.16.12.1894}, issn = {13035150}, year = {2018}, date = {2018-01-01}, journal = {NeuroQuantology}, volume = {16}, number = {12}, pages = {86-97}, publisher = {Anka Publishers}, abstract = {Obesity and overweight are frequently prescribed for dysfunction in food-intake behavior. Due to the widely prevalence of obesity in last year’s, there is demand for more studies which are aimed to modify the food-intake behavior. For the past decades many researches has applied in modify food-intake by brain training or stimulation. This review for neuroscience studies in modifying food-intake behavior, it’s involved three sections; The first section explained the role of brain activity in food-intake regulation, general ideas about biomedical devices in food-intake behavior are discussed in second section and third section focused on brain-stimulation systems. Finally, this paper concluded with main points that need to be taken into account when designing experimental study for modification food-intake behavior by brain stimulation according to previous studies recommendation and challenges. © 2018, Anka Publishers. All Rights Reserved.}, note = {cited By 2}, keywords = {Amygdala, Anoxia, Article, Autism, Binge Eating Disorder, Body Mass, Body Weight, Brain Depth Stimulation, Depolarization, Dietary Intake, Drug Craving, Eating Disorder, Electric Current, Electroencephalogram, Electroencephalography, Energy Consumption, Energy Expenditure, Feeding Behavior, Food Intake, Functional Magnetic Resonance Imaging, Gender, Health Status, Homeostasis, Human, Hunger, Lifestyle, Nerve Cell Membrane Steady Potential, Nerve Excitability, Neurofeedback, Neuromodulation, Nutritional Assessment, Outcome Assessment, Questionnaires, Repetitive Transcranial Magnetic Stimulation, Signal Processing, Training, Transcranial Direct Current Stimulation, Transcranial Magnetic Stimulation, Underweight}, pubstate = {published}, tppubtype = {article} } Obesity and overweight are frequently prescribed for dysfunction in food-intake behavior. Due to the widely prevalence of obesity in last year’s, there is demand for more studies which are aimed to modify the food-intake behavior. For the past decades many researches has applied in modify food-intake by brain training or stimulation. This review for neuroscience studies in modifying food-intake behavior, it’s involved three sections; The first section explained the role of brain activity in food-intake regulation, general ideas about biomedical devices in food-intake behavior are discussed in second section and third section focused on brain-stimulation systems. Finally, this paper concluded with main points that need to be taken into account when designing experimental study for modification food-intake behavior by brain stimulation according to previous studies recommendation and challenges. © 2018, Anka Publishers. All Rights Reserved. |
2016 |
Tan, M L; Ho, J J; Teh, K H Polyunsaturated fatty acids (PUFAs) for children with specific learning disorders Journal Article Cochrane Database of Systematic Reviews, 2016 (9), 2016, ISSN: 1469493X, (cited By 6). Abstract | Links | BibTeX | Tags: Attention Deficit Disorder, Autism, Carnosine, Children, Diet Supplementation, Drug Effect, Gastrointestinal Symptom, Human, Learning Disorder, Meta Analysis, Outcome Assessment, Placebo, Polyunsaturated Fatty Acid, Priority Journal, Randomized Controlled Trial, Review, Systematic Review @article{Tan2016, title = {Polyunsaturated fatty acids (PUFAs) for children with specific learning disorders}, author = {M L Tan and J J Ho and K H Teh}, url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84988922340&doi=10.1002%2f14651858.CD009398.pub3&partnerID=40&md5=3460f403b8829b4692a0b6f795f4a2a3}, doi = {10.1002/14651858.CD009398.pub3}, issn = {1469493X}, year = {2016}, date = {2016-01-01}, journal = {Cochrane Database of Systematic Reviews}, volume = {2016}, number = {9}, publisher = {John Wiley and Sons Ltd}, abstract = {Background: About 5% of school children have a specific learning disorder, defined as unexpected failure to acquire adequate abilities in reading, writing or mathematics that is not a result of reduced intellectual ability, inadequate teaching or social deprivation. Of these events, 80% are reading disorders. Polyunsaturated fatty acids (PUFAs), in particular, omega-3 and omega-6 fatty acids, which normally are abundant in the brain and in the retina, are important for learning. Some children with specific learning disorders have been found to be deficient in these PUFAs, and it is argued that supplementation of PUFAs may help these children improve their learning abilities. Objectives: 1. To assess effects on learning outcomes of supplementation of polyunsaturated fatty acids (PUFAs) for children with specific learning disorders.2. To determine whether adverse effects of supplementation of PUFAs are reported in these children. Search methods: In November 2015, we searched CENTRAL, Ovid MEDLINE, Embase, PsycINFO, 10 other databases and two trials registers. We also searched the reference lists of relevant articles. Selection criteria: Randomised controlled trials (RCTs) or quasi-RCTs comparing PUFAs with placebo or no treatment in children younger than 18 years with specific learning disabilities, as diagnosed in accordance with the fifth (or earlier) edition of theDiagnostic and Statistical Manual of Mental Disorders (DSM-5), or the 10th (or earlier) revision of the International Classification of Diseases (ICD-10) or equivalent criteria. We included children with coexisting developmental disorders such as attention deficit hyperactivity disorder (ADHD) or autism. Data collection and analysis: Two review authors (MLT and KHT) independently screened the titles and abstracts of articles identified by the search and eliminated all studies that did not meet the inclusion criteria. We contacted study authors to ask for missing information and clarification, when needed. We used the GRADE approach to assess the quality of evidence. Main results: Two small studies involving 116 children, mainly boys between 10 and 18 years of age, met the inclusion criteria. One study was conducted in a school setting, the other at a specialised clinic. Both studies used three months of a combination of omega-3 and omega-6 supplements as the intervention compared with placebo. Although both studies had generally low risk of bias, we judged the risk of reporting bias as unclear in one study, and as high in the other study. In addition, one of the studies was funded by industry and reported active company involvement in the study. None of the studies reported data on the primary outcomes of reading, writing, spelling and mathematics scores, as assessed by standardised tests. Evidence of low quality indicates that supplementation of PUFAs did not increase the risk of gastrointestinal disturbances (risk ratio 1.43, 95% confidence interval 0.25 to 8.15; two studies, 116 children). Investigators reported no other adverse effects. Both studies reported attention deficit hyperactivity disorder (ADHD)-related behaviour outcomes. We were unable to combine the results in a meta-analysis because one study reported findings as a continuous outcome, and the other as a dichotomous outcome. No other secondary outcomes were reported. We excluded one study because it used a cointervention (carnosine), and five other studies because they did not provide a robust diagnosis of a specific learning disorder. We identified one ongoing study and found three studies awaiting classification. Authors' conclusions: Evidence is insufficient to permit any conclusions about the effect of PUFAs on the learning abilities of children with specific learning disorders. Well-designed RCTs with clearly defined populations of children with specific learning disorders who have been diagnosed by standardised diagnostic criteria are needed. © 2016 The Cochrane Collaboration.}, note = {cited By 6}, keywords = {Attention Deficit Disorder, Autism, Carnosine, Children, Diet Supplementation, Drug Effect, Gastrointestinal Symptom, Human, Learning Disorder, Meta Analysis, Outcome Assessment, Placebo, Polyunsaturated Fatty Acid, Priority Journal, Randomized Controlled Trial, Review, Systematic Review}, pubstate = {published}, tppubtype = {article} } Background: About 5% of school children have a specific learning disorder, defined as unexpected failure to acquire adequate abilities in reading, writing or mathematics that is not a result of reduced intellectual ability, inadequate teaching or social deprivation. Of these events, 80% are reading disorders. Polyunsaturated fatty acids (PUFAs), in particular, omega-3 and omega-6 fatty acids, which normally are abundant in the brain and in the retina, are important for learning. Some children with specific learning disorders have been found to be deficient in these PUFAs, and it is argued that supplementation of PUFAs may help these children improve their learning abilities. Objectives: 1. To assess effects on learning outcomes of supplementation of polyunsaturated fatty acids (PUFAs) for children with specific learning disorders.2. To determine whether adverse effects of supplementation of PUFAs are reported in these children. Search methods: In November 2015, we searched CENTRAL, Ovid MEDLINE, Embase, PsycINFO, 10 other databases and two trials registers. We also searched the reference lists of relevant articles. Selection criteria: Randomised controlled trials (RCTs) or quasi-RCTs comparing PUFAs with placebo or no treatment in children younger than 18 years with specific learning disabilities, as diagnosed in accordance with the fifth (or earlier) edition of theDiagnostic and Statistical Manual of Mental Disorders (DSM-5), or the 10th (or earlier) revision of the International Classification of Diseases (ICD-10) or equivalent criteria. We included children with coexisting developmental disorders such as attention deficit hyperactivity disorder (ADHD) or autism. Data collection and analysis: Two review authors (MLT and KHT) independently screened the titles and abstracts of articles identified by the search and eliminated all studies that did not meet the inclusion criteria. We contacted study authors to ask for missing information and clarification, when needed. We used the GRADE approach to assess the quality of evidence. Main results: Two small studies involving 116 children, mainly boys between 10 and 18 years of age, met the inclusion criteria. One study was conducted in a school setting, the other at a specialised clinic. Both studies used three months of a combination of omega-3 and omega-6 supplements as the intervention compared with placebo. Although both studies had generally low risk of bias, we judged the risk of reporting bias as unclear in one study, and as high in the other study. In addition, one of the studies was funded by industry and reported active company involvement in the study. None of the studies reported data on the primary outcomes of reading, writing, spelling and mathematics scores, as assessed by standardised tests. Evidence of low quality indicates that supplementation of PUFAs did not increase the risk of gastrointestinal disturbances (risk ratio 1.43, 95% confidence interval 0.25 to 8.15; two studies, 116 children). Investigators reported no other adverse effects. Both studies reported attention deficit hyperactivity disorder (ADHD)-related behaviour outcomes. We were unable to combine the results in a meta-analysis because one study reported findings as a continuous outcome, and the other as a dichotomous outcome. No other secondary outcomes were reported. We excluded one study because it used a cointervention (carnosine), and five other studies because they did not provide a robust diagnosis of a specific learning disorder. We identified one ongoing study and found three studies awaiting classification. Authors' conclusions: Evidence is insufficient to permit any conclusions about the effect of PUFAs on the learning abilities of children with specific learning disorders. Well-designed RCTs with clearly defined populations of children with specific learning disorders who have been diagnosed by standardised diagnostic criteria are needed. © 2016 The Cochrane Collaboration. |
2015 |
Alwi, N; Harun, D; Leonard, J H Clinical application of sensory integration therapy for children with autism Journal Article Egyptian Journal of Medical Human Genetics, 16 (4), pp. 393-394, 2015, ISSN: 11108630, (cited By 1). Links | BibTeX | Tags: Autism, Disease Severity, Groups by Age, Human, Letter, Motor Performance, Outcome Assessment, Sensorimotor Integration, Therapy, Therapy Effect, Treatment Indication, Treatment Response @article{Alwi2015393, title = {Clinical application of sensory integration therapy for children with autism}, author = {N Alwi and D Harun and J H Leonard}, url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84940898525&doi=10.1016%2fj.ejmhg.2015.05.009&partnerID=40&md5=5548f0db22520a480f09da9aaf4c872e}, doi = {10.1016/j.ejmhg.2015.05.009}, issn = {11108630}, year = {2015}, date = {2015-01-01}, journal = {Egyptian Journal of Medical Human Genetics}, volume = {16}, number = {4}, pages = {393-394}, publisher = {Egyptian Society of Human Genetics}, note = {cited By 1}, keywords = {Autism, Disease Severity, Groups by Age, Human, Letter, Motor Performance, Outcome Assessment, Sensorimotor Integration, Therapy, Therapy Effect, Treatment Indication, Treatment Response}, pubstate = {published}, tppubtype = {article} } |
2010 |
Patel, V; Maj, M; Flisher, A J; Silva, De M J; Koschorke, M; Prince, M; Tempier, R; Riba, M B; Sanchez, M; Campodonico, F D; Risco, L; Gask, L; Wahlberg, H; Roca, M; Lecic-Tosevski, D; Soghoyan, A; Moussaoui, D; Baddoura, C; Adeyemi, J; Rataemane, S; Jalili, S A; Mohandas, E; Shinfuku, N; Freidin, J; Stagnaro, J C; Puig, I J; Kirkby, K; Musalek, M; Ismayilov, N; Rabbani, G; Harvey, S; Sabbe, B; Noya-Tapia, N; Burgic-Radmanovic, M; Hetem, L A; Vasconcellos, F; Maass, J; Miranda, C; Papaneophytou, N; Raboch, J; Fink-Jensen, A; Okasha, A; Korkeila, J; Guelfi, J D; Schneider, F; Ohene, S; Christodoulou, G; Soldatos, C R; Barrera, S K E Q; Mendoza, M; Kallivayalil, R A; Gudarzi, S S; Lafta, M R; Bassi, M; Clerici, M; Gibson, R; Kojima, T; Nurmagambetova, S; Cho, S -C; Kadyrova, T; Mikati, N; Bajraktarov, S; Yen, T H; Ayushjav, B; Stevovic, L I; Molina, J S S; Gureje, O; Johannessen, J O; Chaudhry, H R; Al-Ashhab, B; Araszkiewicz, A; Prelipceanu, D; Krasnov, V; Bogdanov, A; Jasovic-Gasic, M; Vavrusova, L; Pregelj, P; Liria, A F; Abdelrahman, A; Udomratn, P; Ulas, H; Gokaip, P; Kigozi, F N; Richardson, G Reducing the treatment gap for mental disorders: A WPA survey Journal Article World Psychiatry, 9 (3), pp. 169-176, 2010, ISSN: 17238617, (cited By 127). Abstract | Links | BibTeX | Tags: Anxiety Disorder, Article, Atomoxetine, Atypical Antipsychotic Agent, Autism, Benzodiazepine, Bipolar Disorder, Central Nervous System Stimulants, Cholinesterase Inhibitor, Cognitive Therapy, Community Mental Health Center, Conduct Disorder, Cost Effectiveness Analysis, Dementia, Depression, Evidence-based Practice, Family, Family Therapy, Haloperidol, Health Care, Health Care Access, Health Care Delivery, Health Care Personnel, Health Practitioner, Health Survey, Help Seeking Behavior, Home Mental Health Care, Human, Hyperkinesia, Long Term Care, Lowest Income Group, Mental Deficiency, Mental Disease, Mental Health, Mental Health Care, Mental Health Service, Nootropic Agent, Open Ended Questionnaire, Outcome Assessment, Patient Compliance, Personality Disorder, Practice Guideline, Priority Journal, Psychiatry, Psychoeducation, Psychotherapy, Schizophrenia, Serotonin Noradrenalin Reuptake Inhibitor, Serotonin Uptake Inhibitor, Substance Abuse, Therapy, Therapy Delay, Tricyclic Antidepressant Agent, World Health Organization @article{Patel2010169, title = {Reducing the treatment gap for mental disorders: A WPA survey}, author = {V Patel and M Maj and A J Flisher and M J De Silva and M Koschorke and M Prince and R Tempier and M B Riba and M Sanchez and F D Campodonico and L Risco and L Gask and H Wahlberg and M Roca and D Lecic-Tosevski and A Soghoyan and D Moussaoui and C Baddoura and J Adeyemi and S Rataemane and S A Jalili and E Mohandas and N Shinfuku and J Freidin and J C Stagnaro and I J Puig and K Kirkby and M Musalek and N Ismayilov and G Rabbani and S Harvey and B Sabbe and N Noya-Tapia and M Burgic-Radmanovic and L A Hetem and F Vasconcellos and J Maass and C Miranda and N Papaneophytou and J Raboch and A Fink-Jensen and A Okasha and J Korkeila and J D Guelfi and F Schneider and S Ohene and G Christodoulou and C R Soldatos and S K E Q Barrera and M Mendoza and R A Kallivayalil and S S Gudarzi and M R Lafta and M Bassi and M Clerici and R Gibson and T Kojima and S Nurmagambetova and S -C Cho and T Kadyrova and N Mikati and S Bajraktarov and T H Yen and B Ayushjav and L I Stevovic and J S S Molina and O Gureje and J O Johannessen and H R Chaudhry and B Al-Ashhab and A Araszkiewicz and D Prelipceanu and V Krasnov and A Bogdanov and M Jasovic-Gasic and L Vavrusova and P Pregelj and A F Liria and A Abdelrahman and P Udomratn and H Ulas and P Gokaip and F N Kigozi and G Richardson}, url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-79851492757&doi=10.1002%2fj.2051-5545.2010.tb00305.x&partnerID=40&md5=ebf47e1e84f22271aea10a73c93e9892}, doi = {10.1002/j.2051-5545.2010.tb00305.x}, issn = {17238617}, year = {2010}, date = {2010-01-01}, journal = {World Psychiatry}, volume = {9}, number = {3}, pages = {169-176}, publisher = {Blackwell Publishing Ltd}, abstract = {The treatment gap for people with mental disorders exceeds 50% in all countries of the world, approaching astonishingly high rates of 90% in the least resourced countries. We report the findings of the first systematic survey of leaders of psychiatry in nearly 60 countries on the strategies for reducing the treatment gap. We sought to elicit the views of these representatives on the roles of different human resources and health care settings in delivering care and on the importance of a range of strategies to increase the coverage of evidence-based treatments for priority mental disorders for each demographic stage (childhood, adolescence, adulthood and old age). Our findings clearly indicate three strategies for reducing the treatment gap: increasing the numbers of psychiatrists and other mental health professionals; increasing the involvement of a range of appropriately trained non-specialist providers; and the active involvement of people affected by mental disorders. This is true for both high income and low/middle income countries, though relatively of more importance in the latter. We view this survey as a critically important first step in ascertaining the position of psychiatrists, one of the most influential stakeholder communities in global mental health, in addressing the global challenge of scaling up mental health services to reduce the treatment gap.}, note = {cited By 127}, keywords = {Anxiety Disorder, Article, Atomoxetine, Atypical Antipsychotic Agent, Autism, Benzodiazepine, Bipolar Disorder, Central Nervous System Stimulants, Cholinesterase Inhibitor, Cognitive Therapy, Community Mental Health Center, Conduct Disorder, Cost Effectiveness Analysis, Dementia, Depression, Evidence-based Practice, Family, Family Therapy, Haloperidol, Health Care, Health Care Access, Health Care Delivery, Health Care Personnel, Health Practitioner, Health Survey, Help Seeking Behavior, Home Mental Health Care, Human, Hyperkinesia, Long Term Care, Lowest Income Group, Mental Deficiency, Mental Disease, Mental Health, Mental Health Care, Mental Health Service, Nootropic Agent, Open Ended Questionnaire, Outcome Assessment, Patient Compliance, Personality Disorder, Practice Guideline, Priority Journal, Psychiatry, Psychoeducation, Psychotherapy, Schizophrenia, Serotonin Noradrenalin Reuptake Inhibitor, Serotonin Uptake Inhibitor, Substance Abuse, Therapy, Therapy Delay, Tricyclic Antidepressant Agent, World Health Organization}, pubstate = {published}, tppubtype = {article} } The treatment gap for people with mental disorders exceeds 50% in all countries of the world, approaching astonishingly high rates of 90% in the least resourced countries. We report the findings of the first systematic survey of leaders of psychiatry in nearly 60 countries on the strategies for reducing the treatment gap. We sought to elicit the views of these representatives on the roles of different human resources and health care settings in delivering care and on the importance of a range of strategies to increase the coverage of evidence-based treatments for priority mental disorders for each demographic stage (childhood, adolescence, adulthood and old age). Our findings clearly indicate three strategies for reducing the treatment gap: increasing the numbers of psychiatrists and other mental health professionals; increasing the involvement of a range of appropriately trained non-specialist providers; and the active involvement of people affected by mental disorders. This is true for both high income and low/middle income countries, though relatively of more importance in the latter. We view this survey as a critically important first step in ascertaining the position of psychiatrists, one of the most influential stakeholder communities in global mental health, in addressing the global challenge of scaling up mental health services to reduce the treatment gap. |
Testingadminnaacuitm2020-05-28T06:49:14+00:00
2018 |
A review in modification food-intake behavior by brain stimulation: Excess weight cases Journal Article NeuroQuantology, 16 (12), pp. 86-97, 2018, ISSN: 13035150, (cited By 2). |
2016 |
Polyunsaturated fatty acids (PUFAs) for children with specific learning disorders Journal Article Cochrane Database of Systematic Reviews, 2016 (9), 2016, ISSN: 1469493X, (cited By 6). |
2015 |
Clinical application of sensory integration therapy for children with autism Journal Article Egyptian Journal of Medical Human Genetics, 16 (4), pp. 393-394, 2015, ISSN: 11108630, (cited By 1). |
2010 |
Reducing the treatment gap for mental disorders: A WPA survey Journal Article World Psychiatry, 9 (3), pp. 169-176, 2010, ISSN: 17238617, (cited By 127). |